CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Take a look around and find current information, news, literature, and other resources from this area of oncology treatment. We hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Sarah Jimenez, DNP, AGACNP-BC, AOCNP
BMT/IEC Advanced Practice Provider
Blood and Marrow Transplantation/Immune Effector Cell Therapy Program
Augusta University/Georgia Cancer Center

The EBMT/EHA CAR-T Cell Handbook

International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

CAR T-Cell Therapy Resource Center

Megan Spychalla, PA-C: Developing a Successful CAR T-Cell Therapy Outpatient Program—Behind the Scenes at the Mayo Clinic

The EBMT/EHA CAR-T Cell Handbook

International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

CAR T-cell Therapy: Beyond the Storm

New England Journal of Medicine Evidence

CD19 CAR T-cell therapy in autoimmune disease–A case series with follow-up

Blood Cancer Journal

Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

The ASCO Post

Novel CAR T-cell therapy under study in relapsed or refractory non-Hodgkin lymphoma

New England Journal of Medicine Evidence

CAR T-cell immunotherapy in minority patients with lymphoma

The Lancet Oncology

Fractionated initial infusion and booster dose of ARI0002h, a humanised BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): A single-arm, multicentre academic pilot study

JAMA Network

CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome

New England Journal of Medicine

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

British Journal of Haematology

Severe persistent neurotoxicity associated with CAR T therapy in children

New England Journal of Medicine

Survival with axicabtagene ciloleucel in large B-cell lymphoma

Lancet

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label single-arm, phase 1-2 study

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Neurologic Toxicity Post-CAR T-Cell Therapy and CRS: Differentiating Symptoms and Individual Management

Fast Facts #12: BCMA Targets